Trebananib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Trebananib
Accession Number
DB12056
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon Cancer, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
Amg 386
Categories
UNII
X8Y5U6NC7E
CAS number
894356-79-7

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Trebananib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Trebananib.Experimental
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Trebananib.Approved, Investigational, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Trebananib.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trebananib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Trebananib.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Trebananib.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Trebananib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Trebananib.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Trebananib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Trebananib.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trebananib.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Trebananib.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Trebananib.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Trebananib.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Trebananib.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Trebananib.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trebananib.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Trebananib.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Trebananib.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Trebananib.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911276

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Solid Neoplasm / Lung Carcinoid Tumor / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Uterine Corpus Sarcoma / Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IIIB Uterine Sarcoma / Stage IIIC Uterine Sarcoma / Stage IV Renal Cell Cancer / Stage IVA Uterine Sarcoma / Stage IVB Uterine Sarcoma1
1CompletedTreatmentAdvanced Solid Tumors2
1CompletedTreatmentAdvanced Solid Tumors / Impaired Renal Function / Kidney Diseases1
1CompletedTreatmentCancer of the Ovary / Cancers / Carcinoma NOS / Fallopian Tube Cancer / Gynecological Malignancies / Metastases / Oncology / Tumors / Tumors, Solid1
1CompletedTreatmentCentral Nervous System Neoplasms / Solid Neoplasms1
1CompletedTreatmentNeoplasms, Advanced Solid1
1CompletedTreatmentTumors1
1RecruitingTreatmentAdvanced Solid Tumors1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentAdult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Oligodendroglioma / Giant Cell Glioblastoma / Glioblastomas / Gliosarcoma / Oligodendrogliomas / Recurrent Adult Brain Neoplasm / Recurrent Brain Neoplasm / Recurrent Glioblastoma1
2Active Not RecruitingTreatmentAdvanced Renal Cell Carcinoma1
2Active Not RecruitingTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2Active Not RecruitingTreatmentProstate Cancer / Prostate Neoplasms / Prostatic Neoplams / Prostatic Neoplasms1
2Active Not RecruitingTreatmentRenal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage III Renal Cell Cancer AJCC v7 / Stage IV Renal Cell Cancer / Stage IV Renal Cell Cancer AJCC V71
2CompletedTreatmentAdult Angiosarcoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentAdvanced Hepatocellular Carcinoma / Inoperable Hepatocellular Carcinoma1
2CompletedTreatmentAdvanced Renal Cell Carcinoma1
2CompletedTreatmentCancers / Carcinoma NOS / Colorectal Cancers / Gastrointestinal Cancers / Malignant Neoplasm of Colon / Metastases / Metastatic Cancers / Metastatic Colorectal Cancers / Oncology / Rectal Carcinoma1
2CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation / Endometrial Serous Adenocarcinoma / Endometrioid Stromal Sarcoma / Recurrent Uterine Corpus Carcinoma1
2CompletedTreatmentGastrointestinal Cancers1
2CompletedTreatmentLocally Recurrent and Metastatic Breast Cancer1
2RecruitingTreatmentCancer, Breast / Neoplasms, Breast / Tumors, Breast1
2WithdrawnTreatmentTransitional Cell Carcinoma1
3CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cancer1
3TerminatedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 15:16 / Updated on March 02, 2018 04:05